CEO Ron Cohen (Acorda)
January 13, 2021 11:06 AM ESTUpdated January 14, 09:58 AM
Deals
Manufacturing

Acor­da of­floads man­u­fac­tur­ing op­er­a­tions to Catal­ent for $70M amid lat­est re­struc­tur­ing to keep the ship afloat

Conner Mitchell

Just over a year af­ter the Supreme Court quashed any hopes Acor­da had of pro­tect­ing its once-lu­cra­tive mul­ti­ple scle­ro­sis drug Ampyra from cheap­er knock­offs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

In­tel­lia touts first clin­i­cal out­comes on CRISPR-based AT­TR amy­loi­do­sis as­set

Scot­tish biotech de­buts with ‘Tro­jan horse’ plat­form for can­cer

Ei­sai ter­mi­nates Phase 3 tri­al of Dravet drug, cit­ing re­cruit­ment chal­lenges

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

Ex­clu­sive: Athena Coun­tou­ri­o­tis' Aven­zo taps Shang­hai biotech for ADC, adds new funds

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times